Isn't Karnauskas overstating the need for Ribavarin? Per abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1 Abbvie's Pearl II-IV trial results , Riba added little or no benefit for non-cirrhotic patients.